Psychiatry

Research Faculty

A photo of Michael Sorter.

Michael T. Sorter, MD Director, Division of Child and Adolescent Psychiatry

Michael T. Sorter, MD, is a clinical and administrative psychiatrist whose career focus has been the expansion, improvement, and administration of clinical psychiatric services for children and families. In 2013, Cincinnati Children’s Hospital Medical Center is the largest pediatric hospital child psychiatric service in the country that offers a full continuum of care, including inpatient, residential, and partial hospital.

513-636-8336 michael.sorter@cchmc.org

A photo of Michael Sorter.

High Res

Michael T. Sorter, MD

Director, Division of Child and Adolescent Psychiatry

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-8336

Email michael.sorter@cchmc.org

Show All

Clinical Interests

Training; pediatric psychopharmacology; residential and inpatient treatment of adolescents; mental retardation; developmental disorders

Education and Training

BS: Zoology, The Ohio State University, Columbus, OH, 1981.

MD: University of Cincinnati, Cincinnati, Ohio, 1985.

Residency: Psychiatry, University of Cincinnati, Cincinnati, OH, 1988.

Fellowship: Child Psychiatry, University of Cincinnati, Cincinnati, OH, 1990.

Certification: General Psychiatry, American Board of Psychiatry and Neurology, 1992; Child and Adolescent Psychiatry, American Board of Psychiatry and Neurology, 1993.

View PubMed Publications

Barzman DH, Mossman D, Appel K, Blom TJ, Strawn JR, Ekhator NN, Patel B, Delbello MP, Sorter M, Klein D, Geracioti TD Jr. The Association Between Salivary Hormone Levels and Children’s Inpatient Aggression: A Pilot Study. Psychiatr Q. 2013 Dec;84(4):475-84.

Barzman D, Mossman D, Sonnier L, Sorter M. Brief Rating of Aggression by Children and Adolescents (BRACHA): A Reliability Study. J Am Acad Psychiatry Law. 2012;40(3):374-82.

Barzman DH, Brackenbury L, Sonnier L, Schnell B, Cassedy A, Salisbury S, Sorter M, Mossman D. Brief Rating of Aggression by Children and Adolescents (BRACHA): Development of a Tool for Assessing Risk of Inpatients’ Aggressive Behavior. J Am Acad Psychiatry Law. 2011;39(2):170-9.

King KA, Strunk CM, Sorter MT. Preliminary Effectiveness of Surviving the Teens Suicide Prevention and Depression Awareness Program on Adolescents’ Suicidality and Self-Efficacy in Performing Help-Seeking Behaviors. J Sch Health. 2011 Sep;81(9):581-90.

Sorter, Michael T. Adolescents in crisis: When to admit for self-harm or aggressive behavior. Current Psychiatry. 9(1) 35-46.

Malloy E, Butt S, Sorter M. Physician Leadership and Quality Improvement in the Acute Child and Adolescent Psychiatric Care Setting. Child Psychiatric Clinics of North America. 2010 January; 19(1):1-19.

DelBello MP, Chang K, Welge JA, Adler, CM, Rana M, Howe M, Brian H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski, SM. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009 Aug; 11(5):483-93.

Kowatch RA, Strawn JR, Sorter MT. Clinical trials support new algorithm for treating pediatric bipolar mania. Current Psychiatry. Nov 2009; v8 i11 p19(9).

Patel NC, Leckinger MM, Matias-Akhtar M, Sorter MT, Barzman DH, Morrison JA, Strakowski SM, DelBello MP: Body Mass Indices and Lipid Profiles in Hospitalized Children and Adolescents Exposed to Atypical Antipsychotics. J Child Adolesc Psychopharmacol. 2007 June; 17(3): 303-11.

Nassr N, von Richter O, Jin L, Nebert DW. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics. 2006 May; 16(5):359-67.

A photo of Drew Barzman.

Drew H. Barzman, MD Director, Child and Adolescent Forensic Psychiatry Service

Drew H. Barzman, MD, and his child forensic research team developed the Brief Rating of Aggression by Children and Adolescents (BRACHA), a reliable instrument for predicting aggression and violence in the hospital. His team has also studied salivary biomarkers associated with future aggression by children. Currently, his team is combining fMRI, salivary biomarkers and the BRACHA to better predict pediatric aggression and violence. In addition, his child forensic team has developed one the largest databases on pediatric aggression and violence for analysis.

513-636-8727 drew.barzman@cchmc.org

A photo of Drew Barzman.

High Res

Drew H. Barzman, MD

Director, Child and Adolescent Forensic Psychiatry Service

Academic Affiliations

Associate Professor, N/A

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-8727

Fax 513-636-4788

Email drew.barzman@cchmc.org

Show All

Clinical & Research Interests

Clinical

Child and adolescent forensic psychiatry

Research

Child and adolescent forensic psychiatry; prevention of violence in youth; neuroimaging in children and adolescents; genetics; pediatric clinical trials

Dr. Barzman’s most significant professional achievements include helping children and families, research, and mentoring undergraduate and graduate students.

Education and Training

MD: Buffalo, School of Medicine, State University of New York, 1997.

Residency: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 1997-2001.

Fellowship: Forensic Fellow, Department of Psychiatry, University of Cincinnati, Cincinnati, OH, 2001-2002.

Fellowship: Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, 2002-2004.

Licensure: State of Ohio Medical License, 2001.

Certifications: Psychiatry, 2002; Forensic Psychiatry, 2003; Child and Adolescent Psychiatry, 2004; Dr. Barzman successfully passed the Maintenance of Certification Examination in Psychiatry, Forensic Psychiatry, and Child and Adolescent Psychiatry in April 2011.

Recertification: Passed Modular Examination for Maintenance of Certification in the Specialty of Psychiatry and the Subspecialties of Forensic Psychiatry and Child and Adolescent Psychiatry in April 2011.

View PubMed Publications

Barzman D, Mossman D, Appel K, Blom T, Strawn J, Ekhator N, Patel B, DelBello M, Sorter M, Klein D, Geracioti T. The Association Between Salivary Hormone Levels and Children’s Inpatient Aggression: A Pilot Study. Psychiatr Q. 2013 Dec;84(4):475-84.

Barzman D, Mossman D, Sonnier L, Sorter M. Brief Rating of Aggression by Children and Adolescents (BRACHA): A Reliability Study. J Am Acad Psychiatry Law. 2012;40(3):374-82.

Barzman D, Brackenbury L, Sonnier L, Schnell B, Cassedy A, Salisbury S, Sorter M, Mossman D. Brief Rating of Aggression by Children and Adolescents (BRACHA): Development of a Tool to Assess Risk of Inpatients’ Aggressive Behavior. J Am Acad Psychiatry Law. 2011;39(2):170-9.

Barzman D, Patel A, Sonnier L, Strawn J. Neuroendocrine Aspects of Pediatric Aggression: Can Hormone Measures Be Clinically Useful? Neuropsychiatr Dis Treat. 2010;6:691-7.

Brackenbury L, Barzman D, Dunseith Neal. Evaluating Forensic Interviewing of Children in Sexual Abuse Cases: Guidelines for the Forensic Psychiatrist. Am J Forensic Psychiatry. 2009;30 (2).

Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in children. Int Rev Psychiatry. 2008 Apr;20(2):151-7.

Barzman DH, Delbello MP, Fleck DE, Lehmkuhl H, Strakowski SM. Rates, types, and psychosocial correlates of legal charges in adolescents with newly diagnosed bipolar disorder. Bipolar Disorders. 2007;9(4):339-44.

Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM. The Efficacy and Tolerability of Quetiapine versus Divalproex for the Treatment of Impulsivity and Reactive Aggression in Adolescents with Co-occurring Bipolar Disorder and Disruptive Behavior Disorder(s). J Child Adolesc Psychopharmacol. 2006;16(6):665-70.

DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA., Barzman DH, Nelson E, Strakowski SM. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45:305-13.

Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S, Rappaport K, Delgado SV, Pamela Campbell, Strakowski SM. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14:593-600.

A photo of Sergio Delgado.

Sergio V. Delgado, MD Medical Director of Outpatient Services, Division of Child and Adolescent Psychiatry

Sergio V. Delgado, MD, is a clinical investigator who has clinical trial research programs in depression in the Division of Psychiatry.

513-636-4788 sergio.delgado@cchmc.org

A photo of Sergio Delgado.

High Res

Sergio V. Delgado, MD

Medical Director of Outpatient Services, Division of Child and Adolescent Psychiatry

Chair, Child Psychoanalytic Program

Academic Affiliations

Professor, N/A

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-4788

Email sergio.delgado@cchmc.org

Show All

Learning disorders; ADHD; psychotherapy

Dr. Delgado is a professor in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center within the University of Cincinnati. He is the medical director of outpatient services and director of psychotherapy services in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center.

His research involves the pharmacological treatment of children and adolescents with ADHD, bipolar disorders and depression.

He also is a supervising and training adult and child analyst at the Cincinnati Psychoanalytic Institute.

Education and Training

MD: Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 1981.

Residency: Karl Menninger School of Psychiatry, Topeka, KS.

Fellowship: Child and Adolescent Psychiatry, Karl Menninger School of Psychiatry, Topeka, KS.

Certifications: Psychiatry, 1988; Child and Adolescent Psychiatry, 1990; Psychoanalysis, 1994; Child and Adolescent Psychoanalysis, 1994.

View PubMed Publications

Delgado SV, Strawn J. Termination of psychodynamic psychotherapy with adolescents: a review and contemporary perspective. Bulletin of the Menninger Clinic. 2012;76(1):21-52.

Delgado SV, Wassenaar E, Strawn J. Psychiatric disorder or nonverbal learning disorder? Current Psychiatry. 2011;10(5):17-34.

Kowatch RA, Monroe E, Delgado SV. Not all mood swings are bipolar disorder. Current Psychiatry. 2011;10(2):39-52.

Harris E, Eng HY, Kowatch R, Delgado SV, Saldana SN. Disinhibition as a Side Effect of Treatment with Fluvoxamine in Pediatric Patients with Obsessive Compulsive Disorder. J Child Adolesc Psychopharmacol. 2010.

DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11:483–493.

Delgado, SV. Psychotherapy Rounds. Psychodynamic Psychotherapy for Children and Adolescents: An Old Friend Revisited. Psychiatry. 2008;5(5):67-72.

A photo of Kelli Dominick.

Kelli C. Dominick, MD, PhD Psychiatrist, Division of Child and Adolescent Psychiatry

Dr. Dominick is a clinical researcher, pediatrician and child psychiatrist who specializes in the clinical care and research of neurodevelopmental disorders. Her primary research interest is in the use of neuroimaging to examine neural development, early identification and treatment in autism spectrum disorder and Fragile X Syndrome.

513-636-4611 kelli.dominick@cchmc.org

A photo of Kelli Dominick.

High Res

Kelli C. Dominick, MD, PhD

Psychiatrist, Division of Child and Adolescent Psychiatry

Academic Affiliation

Assistant Professor

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-4611

Email kelli.dominick@cchmc.org

Show All

Kelli Dominick, MD, PhD, is an assistant professor for the Division of Psychiatry at Cincinnati Children’s Hospital Medical Center who specializes in the clinical care and research in neurodevelopmental disorders including Autism Spectrum Disorder and Fragile X Syndrome. Dr. Dominick received her undergraduate degree in Biology and Psychology at Transylvania University. She then earned her MD and PhD degrees at Boston University School of Medicine where she was awarded a pre-doctoral fellowship (F30 NRSA) from the National Institutes of Health. She completed a combined residency program in pediatrics, adult and child psychiatry at Cincinnati Children’s Hospital Medical Center.

Dr. Dominick’s research interests include the use of neuroimaging to examine neural development, early identification and treatment of autism spectrum disorder and Fragile X Syndrome.

Education and Training

MD, PhD: Boston University School of Medicine, Boston, MA, 2011.

Residency: Pediatrics/Adult Psychiatry/Child Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2016.

Certification: Pediatrics, American Board of Pediatrics.

View PubMed Publications

Dominick K, Wink LK, McDougle CJ, Erickson CA. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology. 2015;25(5):397-401.

Strawn JR, Wegman CJ, Dominick KC, Swartz MS, Wehry AM, Patino LR, Strakowski SM, Adler CM, Eliassen JC, DelBello MP. Cortical surface anatomy in pediatric patients with generalized anxiety disorder. Journal of Anxiety Disorders. 2014;28:717-723.

Strawn JR, Dominick KC, Patino L, Doyle CD, Picard LS, Phan KL. Neurobiology of pediatric anxiety disorders. Current Behavioral Neuroscience Reports. 2014;1:154-160.

Knaus TA, Silver AM, Kennedy M, Lindgren KA, Dominick KC, Siegel J, Tager-Flusberg H. Language laterality in autism spectrum disorder and typical controls: A functional, volumetric, and diffusion tensor MRI study. Brain & Languag. 2010;112(2):113-120.

Hadjikhani N, Joseph RM, Maoach DS, Naik P, Snyder J, Dominick K, Hoge R, Van den Stock J, Tager-Flusberg H, de Gelder B. Body expressions of emotion do not trigger fear contagion in autism spectrum disorder. Soc Cogn Affect Neurosci. 2009 Mar;4(1):70-8.

Knaus TA, Silver AM, Dominick KC, Schuring MD, Shaffer N, Lindgren KA, Joseph RM, Tager-Flusberg H. Age-Related Changes in the Anatomy of Language Regions in Autism Spectrum Disorder. Brain Imaging and Behavior. 2009;3(1):51-63.

Dominick KC, Davis NO, Lainhart J, Tager-Flusberg H, Folstein S. Atypical behaviors in children with autism and children with a history of language impairment. Research in Developmental Disabilities. 2007;28(2):145-162.

A photo of Craig Erickson.

Craig A. Erickson, MD

Craig A. Erickson, MD, investigates the pathophysiology and clinical manifestations of neurodevelopmental disorders. The goal of his research is to develop new translational treatment options for these populations.
Behavioral and Developmental Neuropsychiatry

513-636-8375 craig.erickson@cchmc.org

A photo of Craig Erickson.

High Res

Craig A. Erickson, MD

Academic Affiliation

Associate Professor

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-8375

Email craig.erickson@cchmc.org

Show All

Fragile X syndrome; autism spectrum disorders

Visit the Erickson-Wink Lab.

Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.

Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.

Education and Training

MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003.

MS: Indiana University School of Medicine, Indianapolis, IN, 2008.

Residency and Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2003-2008.

Certification: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008.

View PubMed Publications

Erickson CA, Ray B, Wink LK, Bayon BL, Pedapati EV, Shaffer R, Schaefer TL, Lahiri DK. Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism. J Psychiatr Res. 2016 Sep 9;84:153-160.

Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatr Dis Treat. 2016 Jun 23;12:1525-38.

Erickson CA, Wink LK, Baindu B, Ray B, Schaefer TL, Pedapati EV, Lahiri DK. Analysis of peripheral amyloid precursor protein in Angelman Syndrome. Am J Med Genet A. 2016 Sep;170(9):2334-7.

Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ, Erickson CA. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016 Apr 21;7:26.

Minshawi NF, Wink LK, Shaffer R, Plawecki MH, Posey DJ, Liu H, Hurwitz S, McDougle CJ, Swiezy NB, Erickson CA. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Mol Autism. 2016 Jan 14;7:2.

Wink LK, Pedapati EV, Horn PS, McDougle CJ, Erickson CA. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015 Oct 14.

Wink LK, Fitzpatrick S, Shaffer R, Melnyk S, Begtrup AH, Fox E, Schaefer TL, Mathieu-Frasier L, Ray B, Lahiri D, Horn PA, Erickson CA. The neurobehavioral and molecular phenotype of Angelman Syndrome. Am J Med Genet A. 2015 Nov;167A(11):2623-8.

Dominick K, Wink LK, McDougle CJ, Erickson CA. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015 Jun;25(5):397-401.

Schaefer TL, Davenport MH, Erickson CA. Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet. 2015 Apr 7;8:75-93.

Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, McDougle CJ, Sokol DK, Lahiri DK. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014 Dec;59:220-8.

John Merck Fund Translational Research Program Award. Principal Investigator. The John Merck Fund. Jan 2013-Dec 2016.

Autism Inpatient Collection Grant. Site Co-Investigator. Simons Foundation and Nancy Lurie Marks Foundation. Oct 2015-Sep 2018.

Fragile X Clinical and Research Consortium Forward Registry and Database. Principal Investigators. Cincinnati Children’s Hospital Medical Center Site. Sept 2012-Dec 2020.

A photo of Richard Gilman.

Richard C. Gilman, PhD Psychologist, Division of Child and Adolescent Psychiatry

Richard C. Gilman, PhD, is a licensed psychologist who conducts research on risk and resiliency factors in physical and mental health. His work focuses on how environmental factors such as schools, families, and peers, play an important role in psychological and social functioning.

513-636-8172 richard.gilman@cchmc.org

A photo of Richard Gilman.

High Res

Richard C. Gilman, PhD

Psychologist, Division of Child and Adolescent Psychiatry

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-8172

Email richard.gilman@cchmc.org

Show All

Depression; anxiety; adjustment issues; learning issues

Dr. Gilman is a fellow in the American Psychological Association (Division 16, school psychology) and a fellow in the International Society for Quality of Life Studies. He is the author of The Handbook of Positive Psychology in Schools (now undergoing its second revision), an associate editor of Behavioural Change and School Psychology Review, and he is on the editorial board of five academic journals. With over 80 peer-reviewed publications, books, and book chapters on risk/resiliency factors in child development, Dr. Gilman’s work has been formally recognized by the American Psychological Association.

Education and Training

PhD: University of South Carolina, Columbia, SC.

Fellowship: Georgia State University Counseling Center, Atlanta, GA.

Residency: Father Flanagan’s Boy’s Home (aka Boy’s Town), Boys Town, NE.

View PubMed Publications

Bowker JC, Adams RE, Fredstrom B, Gilman R. Experiences of being ignored by peers during late adolescence: Linkages to psychological adjustment. Merrill-Palmer Quarterly. 2014 60;3.

Deckman T, DeWall N, Way B, Gilman R, Richman S. Can Marijuana reduce social pain? Social Psychological and Personality Science. 2013 May 14. Online publication.

Gilman R, Chard K, Schumm J. Hope as a change mechanism in the treatment of post-traumatic stress disorder among veterans. Psychological Trauma: Theory, Research, Practice and Policy. 2012 May;4(3):270-277.

Gilman R, Carter-Sowell A, DeWall N, Adams R, Carboni I. Validation of the Ostracism Experiences Scale for adolescents. Psychological Assessment. 2013;25(2): 319-330.

Carboni I, Gilman R. Brokers at risk: Gender differences in the effects of structural position on social stress and life satisfaction. Group Dynamics. 2012 Sep;16(3):218-230.

DeWall CN, Gilman R, Shariff V, Carboni I, Rice KG. Left out, sluggardly, and blue: Low self-control mediates the relationship between ostracism and depression. Personality and Individual Differences. 2012;16:218-230.

Fredstrom B, Adams R, Gilman R. Distinct correlates related to on-line versus in-person peer victimization among adolescents. Journal of Youth and Adolescence. 2011;40:405-415.

Froehlich TE, Anixt J, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman R. Update on environmental risk factors for attention-deficit/hyperactivity disorder. Current Psychiatry Reports. 2011;13:333-344.

Gilman R, Adams R, Nounopolous A. The interpersonal relationships and social perceptions of adolescent perfectionists. Journal of Research in Adolescence. 2011;21:505-511.

Rice K, Ashby J, Gilman R. Classifying adolescent perfectionists. Psychological Assessment. 2011;23:583-577.

Elana Harris, MD, PhD

Elana Harris, MD, PhD, is a neuroscientist with basic and translational interest in the neurophysiological underpinnings of obsessive-compulsive disorder. She uses magnetoencephalography to examine the frequency of oscillations in various components of the circuitry that supports this condition. Predicting treatment outcome is another focus of the lab.

513-636-2100 elana.harris@cchmc.org

DefaultUser

Elana Harris, MD, PhD

Academic Affiliations

Assistant Professor, N/A

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-2100

Email elana.harris@cchmc.org

Show All

Conditions: anxiety disorders; obsessive compulsive disorder; Tourette syndrome; trichotillomania

Treatment modalities: habit reversal therapy; pharmacotherapy

Education and Training

MD: State University of New York, Downstate Medical Center.

PhD: Neural and Behavioral Science; State University of New York, Downstate Medical Center.

Internship: Pediatrics, Winthrop University Hospital, Mineola, NY.

Residency: Psychiatry, Johns Hopkins Hospital, Baltimore, MD.

Fellowship: Child and Adolescent Psychiatry, Johns Hopkins Hospital, Baltimore, MD.

Korostenskaja M, Wilson A, Rose D, Brunner P, Schalk G, Leach J, Mangano F, Fujiwara H, Rozhkov L, Harris E, Chen PC, Seo JH, Lee KH. Real-time functional mapping (RTFM) with ECoG in pediatric epilepsy surgery: comparison with fMRI and ESM findings. EEG and Clinical Neuroscience. 2013.

Korostenskaja M, Harris E, Giovanetti C, Horn P, Wang Y, Rose D, Fujiwara H, Xiang J. Magnetoencephalography reveals altered auditory information processing in youth with obsessive compulsive disorder. Psychiat Res: Neuroim. 2013;212:132-140.

Wu SW, Harris E, Gilbert DL. Tic suppression: the medical model. J Child Adolesc Psychopharmacol. 2010;20(4):263-76.

Harris E, Wu S. Children with tic disorders: How to match treatment with symptoms. Current Psychiatry. 2010;9(3):29-36.

Harris E, Eng HY, Kowatch R, Delgado SV, Saldaña SN. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010;20(4):347-33.

A photo of Emily Harris.

Emily Harris, MD, MPH, FAAP Psychiatrist, Division of Psychiatry

Emily Harris, MD, MPH, FAAP, is a general pediatrician within the primary care centers associated with the Division of General and Community Pediatrics. She also works as a child and adolescent psychiatrist at the College Hill outpatient campus. Her interests include working toward integration of mental health into primary care practice.

emily.harris@cchmc.org

A photo of Brian Kurtz.

Brian P. Kurtz, MD Attending Psychiatrist, Division of Child and Adolescent Psychiatry

Brian P. Kurtz, MD, is the director of the Psychiatry Consultation-Liaison Service at Cincinnati Children's. Prior to joining the faculty in 2011, he was the director of the Pediatric Consultation-Liaison Psychiatry Program at Tufts Medical Center in Boston, MA.

513-636-4788 brian.kurtz@cchmc.org

A photo of Katherine Lee.

Katherine Lee, MD Psychiatrist, Division of Child and Adolescent Psychiatry

513-636-9900 katherine.lee@cchmc.org

A photo of Daniel Medeiros Almeida.

Daniel Medeiros Almeida, MD Attending Psychiatrist, Division of Child and Adolescent Psychiatry

Daniel Medeiros Almeida, MD, investigates long-chain omega-3 fatty acid (omega-3) levels and cognitive functions, primarily declarative memory, in adolescents with depressive disorders. The goal of this research is to target modifiable risk factors for poor academic outcomes in this population. The role of omega-3 fatty acids in neuronal differentiation, synaptogenesis and synaptic function has been gaining increasing scientific interest.

513-636-4788 daniel.almeida2@cchmc.org

A photo of Ernest Pedapati.

Ernest Pedapati, MD, MS, FAAP

Ernest Pedapati, MD, MS, FAAP, is the director of the Cincinnati Children's Interventional Psychiatry Research Laboratory which is a non-surgical brain stimulation research program investigating childhood neurodevelopmental and psychiatric disorders. This laboratory represents an expansion of the well-established child neurology Gilbert TMS Lab.
Visit the Gilbert / Wu / Pedapati Lab.

513-636-4611 ernest.pedapati@cchmc.org

A photo of Ernest Pedapati.

High Res

Ernest Pedapati, MD, MS, FAAP

Academic Affiliations

Assistant Professor, N/A

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-4611

Email ernest.pedapati@cchmc.org

Show All

Clinical & Research Interests

Clinical

Neurodevelopmental disorders; autism spectrum disorders; fragile X; genetic disorders; schizophrenia

Research

Transcranial magnetic stimulation; transcranial direct current stimulation; TMS; TDCS; EEG; autism; fragile x; eye tracking; electrophysiology.

Visit the Gilbert / Wu / Pedapati Lab.

Dr. Pedapati specializes in the treatment of neuropsychiatric disease associated with ASD, genetic and other neurodevelopmental disorders including interdisciplinary treatment planning and advanced medication management. Prior to his faculty appointment, he had clinical and research training under Craig Erickson, MD, and pediatric transcranial magnetic stimulation under Donald Gilbert, MD, MS.

In 2013, the PI was successful in designing and obtaining IRB approval and competitive funding for a TMS project through the American Academy of Child & Adolescent Psychiatry Pilot Research Award and currently completing the study, "Cortical Plasticity in Adolescent Depression" which attempts to use TMS to determine whether abnormal neuroplasticity can be quantified in adolescent depression.

In his final year of residency, he applied and secured a highly competitive institutional mentor career development award (Proctor Scholar) to support 90% time dedicated to independent research activities including obtaining preliminary data on TMS measures of cortical plasticity in ASD and the development of an implicit false belief task of social cognition for future TMS modulation. In addition he continues to be an active subinvestigator extensively contributing to NIH R01 project examining TMS measures of motor physiology in ADHD pioneered the use of SICI as a biomarker in ADHD and measurement of cortical plasticity in healthy youth.

Education and Training

MD: University of Massachusetts, Worcester, MA, 2009.

Residency: Pediatrics/Adult Psychiatry/Child Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, American Board of Pediatrics.

View PubMed Publications

Wink LK, O’Melia AM, Shaffer RC, Pedapati E, Friedmann K, Schaefer T, Erickson CA. Intranasal Ketamine Treatment in an Adult with Autism Spectrum Disorder. J Clin. Psychiatry. 2014.

Pedapati, EV, Bateman, SC. Toddlers Requiring Pediatric Intensive Care Admission Following at-home Exposure to Buprenorphine/Naloxone. Pediatric Critical Care Med. 2011;Mar 12(2):102-7.

Rhyee SH, Pedapati EV, Thompson J. Prolonged delirium after quetiapine overdose. Pediatric Emergency Care. 2010 Oct 26;(10):754-6.

Stebbins KJ, Carr MJ, Pedapati EV, Ellis JL. Effect of olvanil on the afferent and efferent function of capsaicin-sensitive C-fibers in guinea pig airways. Eur J Pharmacol. 2003 Jun 27;471(3):205-11.

Anomalous Motor Physiology in ADHD. Subinvestigator. National Institutes of Health/National Institute of Mental Health. Sep 2012-Aug 2017. R01 MH095014.

A photo of Suzanne Sampang.

Suzanne J. Sampang, MD Director of Residency Training, Division of Child and Adolescent Psychiatry

513-636-7331

A photo of Suzanne Sampang.

High Res

Suzanne J. Sampang, MD

Director of Residency Training, Division of Child and Adolescent Psychiatry

Medical Co-director, Adolescent Inpatient Psychiatry

Academic Affiliations

Associate Professor, N/A

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-7331

Fax 513-636-4283

Show All

Resident education; inpatient adolescent psychiatry; community mental health

Suzanne J. Sampang, MD, joined as a faculty member at Cincinnati Children’s Hospital Medical Center within the University of Cincinnati College of Medicine in 2003, after completion of her fellowship training in child and adolescent psychiatry. She became training director of the fellowship program in 2005.

Her clinical work includes inpatient adolescent psychiatry, outpatient clinic, psychopharmacology and community mental health.

She has held leadership positions in the Cincinnati Psychiatric Society, the Child and Adolescent Psychiatry Council of Cincinnati and Dayton, and the Ohio Psychiatric Physicians Association. She has served as a board examiner for the American Board of Psychiatry and Neurology.

Education and Training

MD: University of the East, Ramon Magsaysay Memorial Medical Center, Philippines, 1997.

Residency: University of Cincinnati College of Medicine / University Hospital, Inc., Cincinnati, OH, 2002.

Fellowship: University of Cincinnati College of Medicine / Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2003.

Certification: Diplomate, Psychiatry, American Board of Psychiatry and Neurology, 2003, 2013; Child and Adolescent Psychiatry, 2003, 2013.

View PubMed Publication

Delbello M, Chang K, Welge J, Adler C, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado S, Sorter M, Strakowski S. A Double-Blind Placebo Controlled Pilot Study of Quetiapine for Adolescents with Depression Associated with Bipolar Disorder. Bipolar Disorder. 2009;11:483-493.

A photo of Logan Wink.

Logan K. Wink, MD

Logan K. Wink, MD, investigates targeted treatment development in autism spectrum disorders (ASD) and associated developmental disabilities. Dr. Wink's research goal is to contribute to the development of new treatment options targeting both associated symptoms and core impairments in ASD and related disorders.
Visit the Erickson/Wink Lab website.

513-636-8375 logan.wink@cchmc.org

A photo of Logan Wink.

High Res

Logan K. Wink, MD

Academic Affiliation

Assistant Professor

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-8375

Email logan.wink@cchmc.org

Show All

Autism spectrum disorders; Angelman syndrome.

Visit the Erickson/Wink Lab website.

Dr. Logan Wink is an assistant professor for the Division of Child Psychiatry at Cincinnati Children’s Hospital Medical Center within the UC Department of Psychiatry and Behavioral Neuroscience. Dr. Wink is a child and adolescent psychiatrist involved in clinical research and clinical care of individuals with developmental disabilities, including autism spectrum disorders and Angelman syndrome.

Her primary research focus is improving clinical care of individuals with developmental disabilities through better understanding the pathology of these disorders and improving pharmacologic treatment.

Education and Training

MD: Indiana University School of Medicine, Indianapolis, IN, 2007.

Residency: Psychiatry, Indiana University School of Medicine, Indianapolis, IN, 2011.

Fellowship: Child and Adolescent Psychiatry, Indiana University School of Medicine, Indianapolis, IN, 2012.

Fellowship: Autism and Developmental Disabilities, Indiana Division of Developmental Disability and Rehabilitative Services and the Indiana University School of Medicine, Department of Psychiatry, 2012.

Certification: Psychiatry Board Certification, 2011; Child and Adolescent Psychiatry Board Certification, 2012.

View PubMed Publications.

Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ, Erickson CA. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016 Apr 21;7:26.

Wink LK, Badran I, Pedapati EV, Sorensen R, Benton SC, Johnson MC, Wissel G, Erickson CA. Clozapine for Drug-Refractory Irritability in Individuals with Developmental Disability. J Child Adolesc Psychopharmacol. 2016 Nov;26(9):843-846.

Minshawi NF, Wink LK, Shaffer R, Plawecki MH, Posey DJ, Liu H, Hurwitz S, McDougle CJ, Swiezy NB, Erickson CA. A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Autism Spectrum Disorders. Molecular Autism. 2016 Jan 14;7:2.

Siegel M, Smith KA, Mazefsky C, Gabriels RL, Erickson C, Kapaln D, Morrow EM, Wink L, Santangelo SL. The autism inpatient collection: methods and preliminary sample description. Molecular Autism. 2015 Nov;6:61.

Wink LK, Pedapati EV, Horn PS, McDougle CJ, Erickson CA. Multiple Antipsychotic Use in Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology. 2015 Oct.

Wink LK, Fitzpatrick S, Shaffer RC, Melnyk S, Schaefer T, Mathieu-Frasier L, Ray B, Lahiri D, Erickson CA. The Neurobehavioral and Molecular Phenotype of Angelman Syndrome. Am J Med Genet A. 2015 Nov;167A(11):2623-8.

Adler BA, Wink LK, Early MC, Shaffer R, Minshawi N, McDougle CJ, Erickson CA. Drug-Refractory Aggression, Self-injurious Behavior, and Severe Tantrums in Autism Spectrum Disorders: A Chart Review Study. Autism. 2015 Jan;19(1):102-6.

Wink LK, O’Melia AM, Shaffer RC, Pedapati E, Friedmann K, Schaefer T, Erickson CA. Intranasal ketamine treatment in an adult with autism spectrum disorder. Journal of Clinical Psychiatry. 2014 Aug;75(8):835-36.

Vasa RA, Carroll LM, Nozzolillo AA, Mahajan R, Mazurek MO, Bennett AE, Wink LK, Bernal MP. A Systematic Review of Treatments for Anxiety in Youth with Autism Spectrum Disorders. J Autism Dev Disord. 2014 Dec;44(12):3215-29.

Wink LK, Early MC, Schaefer T, Bermingham R, Pottenger A, Horn P, McDougle CJ, Erickson CA. Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole. J Child Adolesc Psychopharmacol. 2014 Mar;24(2):78-82.

Investigator-Initiated clinical trial agreement. Principal Investigator. Roivant Sciences Ltd. May 2015-Apr 2017.

Rediscovery Research Award. Principal Investigator. Cures Within Reach. Nov 2015-Apr 2017.

Foundation Grant. Site Principal Investigator. Simons Foundation and Nancy Lurie Marks Foundation, Autism & Developmental Disorders Inpatient Research Collaborative. Apr 2014-Sep 2018.

Clinical Trial Protocol. Site Principal Investigator. Stemina Biomarker Discovery, Children’s Autism Metabolome Project (CAMP). Jun 2015-Jun 2017.

Donate Now